Cell death triggered by alpha-emitting 213Bi-immunoconjugates in HSC45-M2 gastric cancer cells is different from apoptotic cell death
- First Online:
- 111 Downloads
Radioimmunotherapy with α-particle-emitting nuclides, such as 213Bi, is a promising concept for the elimination of small tumour nodules or single disseminated tumour cells. The aim of this study was to investigate cellular damage and the mode of cell death triggered by 213Bi-immunoconjugates.
Human gastric cancer cells (HSC45-M2) expressing d9-E-cadherin were incubated with different levels of activity of 213Bi-d9MAb targeting d9-E-cadherin and 213Bi-d8MAb, which does not bind to d9-E-cadherin. Micronucleated (M) cells, abnormal (A) cells and apoptotic (A) [(MAA)] cells were scored microscopically in the MAA assay following fluorescent staining of nuclei and cytoplasm. Chromosomal aberrations were analysed microscopically following Giemsa staining. The effect of z-VAD-fmk, known to inhibit apoptosis, on the prevention of cell death was investigated following treatment of HSC45-M2 cells with sorbitol as well as 213Bi-d9MAb. Activation of caspase 3 after incubation of HSC45-M2 cells with both sorbitol and 213Bi-d9MAb was analysed via Western blotting.
Following incubation of HSC45-M2 human gastric cancer cells expressing d9-E-cadherin with 213Bi-d9MAb the number of cells killed increased proportional to the applied activity concentration. Microscopically visible effects of α-irradiation of HSC45-M2 cells were formation of micronuclei and severe chromosomal aberrations. Preferential induction of these lesions with specific 213Bi-d9MAb compared with unspecific 213Bi-d8MAb (not targeting d9-E-cadherin) was not observed if the number of floating, i.e. unbound 213Bi-immunoconjugates per cell exceeded 2×104, most likely due to intense crossfire. In contrast to sorbitol-induced cell death, cell death triggered by 213Bi-immunoconjugates was independent of caspase 3 activation and could not be inhibited by z-VAD-fmk, known to suppress the apoptotic pathway.
213Bi-immunoconjugates seem to induce a mode of cell death different from apoptosis in HSC45-M2 cells.
KeywordsAlpha-emitter 213Bi Tumour-specific antibody MAA assay Chromosomal aberrations Caspase 3 activation
- 2.Wiseman GA, Kornmehl E, Leigh B, Erwin WD, Podoloff DA, Spies S, et al. Radiation dosimetry results and safety correlations from 90Y-ibritumomab tiuxetan radioimmunotherapy for relapsed or refractory non-Hodgkin’s lymphoma: combined data from 4 clinical trials. J Nucl Med 2003;44:465–74.PubMedGoogle Scholar
- 3.Bunjes D, Buchmann I, Duncker C, Seitz C, Kotzerke J, Wiesneth M, et al. Rhenium 188-labeled anti-CD66 (a, b, c, e) monoclonal antibody to intensify the conditioning regimen prior to stem cell transplantation for patients with high-risk acute myeloid leukemia or myelodysplastic syndrome: results of a phase I–II study. Blood 2001;78:565–72.CrossRefGoogle Scholar
- 4.Behr TM, Liersch T, Greiner-Bechert L, Griesinger F, Behé MP, Markus PM, et al. Radioimmunotherapy of small-volume disease of metastatic colorectal cancer: results of a phase II trial with the iodine-131-labeled humanized anti-carcinoembryonic antigen antibody hMN-14. Cancer 2002;94:1373–81.PubMedGoogle Scholar
- 6.Reardon DA, Akabani G, Coleman RE, Friedman AH, Friedman HS, Herndon JE, et al. Phase II trial of murine 131I-labeled antitenascin monoclonal antibody 81C6 administered into surgically created resection cavities of patients with newly diagnosed malignant gliomas. J Clin Oncol 2002;20:1389–97.CrossRefPubMedGoogle Scholar
- 13.McDevitt MR, Ma D, Lai LT, Simon J, Borchardt P, Frank RK, et al. Tumor therapy with targeted atomic nanogenerators. Science 2001;294:1537–40.Google Scholar
- 20.Senekowitsch-Schmidtke R, Schuhmacher C, Becker K-F, Nikula TK, Seidl C, Becker I, et al. Highly specific tumor binding of a 213Bi-labeled monoclonal antibody against mutant E-cadherin suggests its usefulness for locoregional α-radioimmunotherapy of diffuse-type gastric cancer. Cancer Res 2001;61:2804–8.PubMedGoogle Scholar
- 21.Miederer M, Seidl C, Beyer G-J, Charlton DE, Vranjes-Duric S, Comor JJ, et al. Comparison of the radiotoxicity of two alpha-particle-emitting immunoconjugates, terbium-149 and bismuth-213, directed against a tumor-specific, exon 9 deleted (d9) E-cadherin adhesion protein. Radiat Res 2003;159:612–20.PubMedGoogle Scholar
- 26.Vandenbuckle K, De Vos F, Offner F, Philippé J, Apostolidis C, Molinet R, et al. In vitro evaluation of 213Bi-rituximab versus external gamma irradiation for the treatment of B-CLL patients: relative biological efficacy with respect to apoptosis induction and the chromosomal damage. Eur J Nucl Med Mol Imaging 2003;30:1357–64.CrossRefPubMedGoogle Scholar
- 31.Apostolidis C, Carlos-Marquez R, Janssens W, Molinet R, Nikula T, Ouadi A. Cancer treatment using Bi-213 and Ac-225 in radioimmunotherapy. Nucl News 2001;44:29–33.Google Scholar
- 36.Mai JC, Mi Z, Kim SH, Ng B, Robbins PD. A proapoptotic peptide for the treatment of solid tumors. Cancer Res 2001;6:7709–12.Google Scholar
- 38.Melle C, Ernst G, Schimmel B, Bleul A, Koscielny S, Wiesner A, et al. Biomarker discovery and identification in laser microdissected head and neck squamous cell carcinoma with ProteinChip® technology, two-dimensional gel electrophoresis, tandem mass spectrometry, and immunohistochemistry. Mol Cell Proteomics 2003;2:443–52.PubMedGoogle Scholar
- 41.Martin SJ, Amarante-Mendes GP, Shi L, Chuang TH, Casiano CA, O’Brien GA, et al. The cytotoxic cell protease granzyme B initiates apoptosis in a cell-free system by proteolytic processing and activation of the ICE/CED-3 family protease, CPP32, via a novel two-step mechanism. EMBO J 1996;15:2407–16.PubMedGoogle Scholar